Initially, there were 4 deaths reported. That number was adjusted to 3 during the night. Wednesday morning there was a new data published: 2 dead and 14 wounded. That balance was re-adjusted Wednesday morning to 3 deaths and 13 wounded. One of the three fatalities has been declared brain dead.

There is still no clarity about the other victim. According to the Belgian Ministry of Foreign Affairs, it would not be a Belgian. But the ministry emphasizes that there is no official confirmation of this yet. Foreign Affairs does not adjust the travel advice for France on its website, but does give a factual representation of the events in Strasbourg for those who visit the travel advice for France.

Among the three deaths caused by the shooting in the French city of Strasbourg is a Thai tourist. According to the Ministry of Foreign Affairs of the Southeast Asian country, it is a 45-year-old man who was on holiday in France with his wife.

It would be Anupong Suebsamarn, reports the Thai PPTV. The couple had arrived in the city shortly before the shooting, according to Thai media. The Thai embassy in Paris now assists his wife. She, Naiyana, remained unharmed. The man died by a bullet wound inflicted to the head.

The gunner, who according to the police presumably had a terrorist motive, is still on the run.

There are many tourists in Strasbourg at this time of the year because of the large Christmas market that takes place there in the center of the city. France has raised the threat level to the highest level.

Minute of silence

In many places in France the flags hang at half-mast. In the French parliament, a minute’s silence will be held around 3 pm on Wednesday. Also in the European Parliament in Strasbourg on Wednesday afternoon a minute of silence was held.

Spectators of a basketball game Tuesday night already paid tribute to the victims by singing the Marseillaise, the French national anthem.

Load More Related Articles
Load More By WeeklyNews staff
Load More In Politics

Leave a Reply

Your email address will not be published. Required fields are marked *

Check Also

Filgotinib isn’t ready for US market yet

The medicine filgotinib by biotechnology Galapagos is not yet ready for approval in its pr…